Allogene Therapeutics Stock Investor Sentiment
| ALLO Stock | USD 2.12 0.07 3.20% |
About 58% of Allogene Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Allogene Therapeutics suggests that many traders are alarmed. Allogene Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Allogene Therapeutics. Many technical investors use Allogene Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Allogene |
Allogene Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Allogene Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Allogene Therapeutics that are available to investors today. That information is available publicly through Allogene media outlets and privately through word of mouth or via Allogene internal channels. However, regardless of the origin, that massive amount of Allogene data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Allogene Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Allogene Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Allogene Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Allogene Therapeutics alpha.
Allogene Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 36404 shares by Geoffrey Parker of Allogene Therapeutics at 2.84 subject to Rule 16b-3 | 10/21/2024 |
2 | Disposition of 24428 shares by Smith Lillian of Allogene Therapeutics at 5.04 subject to Rule 16b-3 | 10/29/2024 |
3 | Editas Q3 Loss Narrower Than Expected, Revenues Decrease YY | 11/05/2024 |
4 | Allogene Therapeutics Inc Q3 2024 Earnings Call Highlights Financial Resilience Amidst ... | 11/08/2024 |
5 | Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus | 11/15/2024 |
6 | Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19CD70 Dual CAR ... | 11/18/2024 |
7 | ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs | 11/19/2024 |
8 | Is Allogene Therapeutics In A Good Position To Invest In Growth | 11/22/2024 |
9 | ACAD Signs License Deal With Saniona for Rights to Neurology Drug | 11/27/2024 |
10 | Allogene Therapeutics, Inc. Sees Large Decrease in Short Interest - MarketBeat | 12/03/2024 |
11 | Disposition of 9221 shares by Humer Franz B of Allogene Therapeutics at 2.16 subject to Rule 16b-3 | 12/05/2024 |
Check out Allogene Therapeutics Hype Analysis, Allogene Therapeutics Correlation and Allogene Therapeutics Performance. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Quarterly Revenue Growth (0.27) | Return On Assets (0.26) | Return On Equity (0.54) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.